Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.

Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.

Item
http://www.wikidata.org/entity/Q34689078
Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3)Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis InhibitorsQuantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patientMiR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinomaNetrin-1 as a potential target for metastatic cancer: focus on colorectal cancer.Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis.Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo.Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.NOD/SCID IL2Rγ-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines.Tiam1 siRNA enhanced the sensitivity of sorafenib on esophageal squamous cell carcinoma in vivo.BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axisEstrogen receptor β ligation inhibits Hodgkin lymphoma growth by inducing autophagy.Exosomal miR-665 as a novel minimally invasive biomarker for hepatocellular carcinoma diagnosis and prognosis.Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo.
P2860

Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.

Item
http://www.wikidata.org/entity/Q34689078
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Sorafenib inhibits lymphoma xe ...... s in tumor and vascular cells.
@ast
Sorafenib inhibits lymphoma xe ...... s in tumor and vascular cells.
@en
Sorafenib inhibits lymphoma xe ...... s in tumor and vascular cells.
@nl
type
label
Sorafenib inhibits lymphoma xe ...... s in tumor and vascular cells.
@ast
Sorafenib inhibits lymphoma xe ...... s in tumor and vascular cells.
@en
Sorafenib inhibits lymphoma xe ...... s in tumor and vascular cells.
@nl
prefLabel
Sorafenib inhibits lymphoma xe ...... s in tumor and vascular cells.
@ast
Sorafenib inhibits lymphoma xe ...... s in tumor and vascular cells.
@en
Sorafenib inhibits lymphoma xe ...... s in tumor and vascular cells.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Sorafenib inhibits lymphoma xe ...... s in tumor and vascular cells.
@en
P2093
P2860
P304
P31
P356
10.1371/JOURNAL.PONE.0061603
P407
P433
P478
P577
P5875
P698
P921
P932